Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in
age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most
important factor involved in this angiogenetic processes in the eye. This forms the basis for
new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the
FDA and one drug is used off-label. All these drugs are administered intravitreally. The
present study aims to directly compare the effects ranibizumab and bevacizumab in a
randomized controlled study in patients with neovascular AMD.
Phase:
Phase 3
Details
Lead Sponsor:
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Collaborators:
Hanuschkrankenhaus Hospital Hietzing Krankenanstalt Rudolfstiftung Krankenhaus der Barmherzigen Brüder Linz Medical University Innsbruck Medical University of Graz Medical University of Vienna Universitätsaugenklinik Salzburg